Condition: Urothelial Carcinoma · Sponsor: Memorial Sloan Kettering Cancer Center
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who are going to have surgery to remove their cancer (cystectomy). The researchers will look at whether treatment with enfortumab vedotin and pembrolizumab before surgery can get rid of cancer within the lymph nodes. They will also try to find out if this combination of drugs is effective at shrinking participants' cancer before their surgery. The researchers think that a combination of enfortumab vedotin and pembrolizumab may help people with this disease because both drugs are designed to help the immune system attack and kill cancer cells. The researchers think the drugs may be more effective if given in combination rather than on their own.
This description comes directly from the study's public registry record.
David Aggen, MD, PhD · 646-422-4679 · aggend@mskcc.org
Jonathan Rosenberg, MD · 646-422-4461
Always discuss trial participation with your own doctor first.
| Baptist Alliance MCI | Miami, Florida, United States | Active Not Recruiting |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering -Nassau | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester | Harrison, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau | Rockville Centre, New York, United States | Recruiting |
| Lehigh Valley Health Network (Data Collection Only) | Allentown, Pennsylvania, United States | Completed |
| University of Texas Southwestern Medical Center at Dallas | Dallas, Texas, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05239624